All Covid-19 updates and resources can be found here: COVID-19 INFORMATION FOR CF COMMUNITY
Skip To Content
Volunteer Advocate

News

All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.


Cystic Fibrosis Canada applauds Ontario, Alberta, and Saskatchewan for listing Trikafta under public drug benefit programs
September 24, 2021

Cystic Fibrosis Canada applauds Ontario, Alberta, and Saskatchewan for listing Trikafta under public drug benefit programs 

Read More
Cystic Fibrosis Canada calls on provinces to list Trikafta immediately, as final recommendation from CADTH issued
September 17, 2021

Provinces pressed to save lives by following guidance from CF clinicians, and fund Trikafta now for all Canadians who can benefit

Read More
Letter to the Honourable François Legault and Christian Dube
September 9, 2021

A letter has been sent to the Honourable François Legault, Premier of the Province of Quebec, and Christian Dubé, Minister of Health, regarding the INESSS recommendation for the cystic fibrosis drug, Trikafta. 

Read More
INESSS IGNORES CLINICAL GUIDELINES AND ISSUES SHORT SIGHTED RECOMMENDATION FOR TRIKAFTA
September 2, 2021

Cystic Fibrosis Canada calls on Quebec Health Minister to save lives by instead following the guidelines developed by CF clinicians, and fund Trikafta now for all Quebecers who can benefit...

Read More
Kin Canada reaches record-breaking $50 million in cumulative donations to Cystic Fibrosis Canada
August 21, 2021

Fundraising milestone a reflection of Kin Canada club members’ decades long commitment to the CF community.

Read More
Cystic Fibrosis Canada calls on provinces to use newest Standards of Care Guidelines and enable urgent access to the life-changing drug, Trikafta
August 17, 2021

 Cystic Fibrosis Canada has published new standardized care guidelines for modulator use in Canada.

Read More
CF Clinicians Speak Out Against Government Recommendations That Could Restrict Access to Miracle Drug Trikafta
August 12, 2021

If implemented, CADTH’s recommendation for the public funding of Trikafta would see access limited to only some of those who could benefit, requiring people to become sicker before offering treatment.

Read More
CADTH FAILS TO FULLY RECOGNIZE GREATEST INNOVATION IN CYSTIC FIBROSIS HISTORY
July 9, 2021

The Canadian Agency for Drugs and Technologies in Health (CADTH) provided this week short sighted and narrow guidance regarding game changing cystic fibrosis (CF) drug Trikafta, that, if adopted by the provinces, could effectively exclude over 25% of eligible Canadians with cystic fibrosis (CF), many of whom are youth, who could greatly benefit from the drug.

Read More
Cystic Fibrosis Canada launches comprehensive study to examine the social and economic impact of life with cystic fibrosis
July 6, 2021

Cystic Fibrosis Canada is providing an exciting opportunity for the cystic fibrosis (CF) community to participate in a new study that will study the impact, both in time and money, that cystic fibrosis has on people living with the disease, their families and on society. Launched today, The Social and Economic Impact of Cystic Fibrosis in Canada: A Burden of Disease Study is open for registrations now until July 25, 2021.

Read More
Health Canada approval of transformational cystic fibrosis medication brings hope to CF community
June 18, 2021

The cystic fibrosis community is closer to its goal today as Health Canada announced the approval of Trikafta for sale in Canada, issuing a Notice of Compliance (NOC). Considered the single greatest innovation in the history of cystic fibrosis, Trikafta is a transformational drug that can change the lives of up to 90% of Canadians with cystic fibrosis. 

Read More